Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Bacterial brothers in arms: cooperation of Staphylococcus aureus and Pseudomonas aeruginosa during antimicrobial exposure.

Lenhard JR, Smith NM, Quach CD, Nguyen TQ, Doan LH, Chau J.

J Antimicrob Chemother. 2019 Sep 1;74(9):2657-2665. doi: 10.1093/jac/dkz247.

PMID:
31219553
2.

Inoculum effect of β-lactam antibiotics.

Lenhard JR, Bulman ZP.

J Antimicrob Chemother. 2019 Oct 1;74(10):2825-2843. doi: 10.1093/jac/dkz226.

PMID:
31170287
3.

Shifting Gears: The Future of Polymyxin Antibiotics.

Lenhard JR, Bulman ZP, Tsuji BT, Kaye KS.

Antibiotics (Basel). 2019 Apr 12;8(2). pii: E42. doi: 10.3390/antibiotics8020042. Review.

4.

Intestinal serine protease inhibition increases FGF21 and improves metabolism in obese mice.

Albarazanji K, Jennis M, Cavanaugh CR, Lang W, Singh B, Lanter JC, Lenhard JM, Hornby PJ.

Am J Physiol Gastrointest Liver Physiol. 2019 May 1;316(5):G653-G667. doi: 10.1152/ajpgi.00404.2018. Epub 2019 Mar 28.

PMID:
30920846
5.
6.

Altered tricarboxylic acid cycle flux in primary myotubes from severely obese humans.

Zou K, Hinkley JM, Park S, Zheng D, Jones TE, Pories WJ, Hornby PJ, Lenhard J, Dohm GL, Houmard JA.

Int J Obes (Lond). 2019 Apr;43(4):895-905. doi: 10.1038/s41366-018-0137-7. Epub 2018 Jun 11.

PMID:
29892037
7.

Time course metabolome of Roux-en-Y gastric bypass confirms correlation between leptin, body weight and the microbiome.

Seridi L, Leo GC, Dohm GL, Pories WJ, Lenhard J.

PLoS One. 2018 May 31;13(5):e0198156. doi: 10.1371/journal.pone.0198156. eCollection 2018.

8.

Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.

Du F, Hinke SA, Cavanaugh C, Polidori D, Wallace N, Kirchner T, Jennis M, Lang W, Kuo GH, Gaul MD, Lenhard J, Demarest K, Ajami NJ, Liang Y, Hornby PJ.

J Pharmacol Exp Ther. 2018 Jun;365(3):676-687. doi: 10.1124/jpet.118.248575. Epub 2018 Apr 19.

PMID:
29674332
9.

Microbiota-derived tryptophan indoles increase after gastric bypass surgery and reduce intestinal permeability in vitro and in vivo.

Jennis M, Cavanaugh CR, Leo GC, Mabus JR, Lenhard J, Hornby PJ.

Neurogastroenterol Motil. 2018 Feb;30(2). doi: 10.1111/nmo.13178. Epub 2017 Aug 7.

PMID:
28782205
10.

Round Robin Study: Molecular Simulation of Thermodynamic Properties from Models with Internal Degrees of Freedom.

Schappals M, Mecklenfeld A, Kröger L, Botan V, Köster A, Stephan S, García EJ, Rutkai G, Raabe G, Klein P, Leonhard K, Glass CW, Lenhard J, Vrabec J, Hasse H.

J Chem Theory Comput. 2017 Sep 12;13(9):4270-4280. doi: 10.1021/acs.jctc.7b00489. Epub 2017 Aug 7.

PMID:
28738147
11.

Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae.

Zhao M, Bulman ZP, Lenhard JR, Satlin MJ, Kreiswirth BN, Walsh TJ, Marrocco A, Bergen PJ, Nation RL, Li J, Zhang J, Tsuji BT.

J Antimicrob Chemother. 2017 Jul 1;72(7):1985-1990. doi: 10.1093/jac/dkx070.

12.

Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.

Lenhard JR, Thamlikitkul V, Silveira FP, Garonzik SM, Tao X, Forrest A, Soo Shin B, Kaye KS, Bulitta JB, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 May 1;72(5):1415-1420. doi: 10.1093/jac/dkx002.

13.

Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.

Bulman ZP, Ly NS, Lenhard JR, Holden PN, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e00096-16. doi: 10.1128/AAC.00096-16. Print 2017 Apr.

14.

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model.

Lenhard JR, Smith NM, Bulman ZP, Tao X, Thamlikitkul V, Shin BS, Nation RL, Li J, Bulitta JB, Tsuji BT.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01268-16. doi: 10.1128/AAC.01268-16. Print 2017 Mar.

15.

In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Int J Antimicrob Agents. 2017 Jan;49(1):25-30. doi: 10.1016/j.ijantimicag.2016.07.015. Epub 2016 Sep 1.

PMID:
27931793
16.

Synergistic combinations of polymyxins.

Lenhard JR, Nation RL, Tsuji BT.

Int J Antimicrob Agents. 2016 Dec;48(6):607-613. doi: 10.1016/j.ijantimicag.2016.09.014. Epub 2016 Oct 24. Review.

17.

Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Lenhard JR, Gall JS, Bulitta JB, Thamlikitkul V, Landersdorfer CB, Forrest A, Nation RL, Li J, Tsuji BT.

Int J Antimicrob Agents. 2016 Dec;48(6):719-724. doi: 10.1016/j.ijantimicag.2016.07.024. Epub 2016 Sep 20.

18.

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah SE, Thamlikitkul V, Shin BS, Rao G, Holden PN, Walsh TJ, Forrest A, Nation RL, Li J, Tsuji BT.

J Antimicrob Chemother. 2017 Jan;72(1):153-165. Epub 2016 Sep 15.

19.

Defining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic Approach.

Garonzik SM, Lenhard JR, Forrest A, Holden PN, Bulitta JB, Tsuji BT.

PLoS One. 2016 Jun 10;11(6):e0156131. doi: 10.1371/journal.pone.0156131. eCollection 2016.

20.

Impact of Staphylococcus aureus accessory gene regulator (agr) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression.

Soon RL, Lenhard JR, Reilly I, Brown T, Forrest A, Tsuji BT.

J Antibiot (Tokyo). 2017 Jan;70(1):98-101. doi: 10.1038/ja.2016.59. Epub 2016 Jun 8. No abstract available.

PMID:
27270303
21.

Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii.

Tsuji BT, Landersdorfer CB, Lenhard JR, Cheah SE, Thamlikitkul V, Rao GG, Holden PN, Forrest A, Bulitta JB, Nation RL, Li J.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3913-20. doi: 10.1128/AAC.02831-15. Print 2016 Jul.

22.

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.

Soon RL, Lenhard JR, Bulman ZP, Holden PN, Kelchlin P, Steenbergen JN, Friedrich LV, Forrest A, Tsuji BT.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):1967-73. doi: 10.1128/AAC.02635-15. Print 2016 Apr.

23.

Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.

Lenhard JR, Brown T, Rybak MJ, Meaney CJ, Norgard NB, Bulman ZP, Brazeau DA, Gill SR, Tsuji BT.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1584-91. doi: 10.1128/AAC.02657-15.

24.

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.

Bergen PJ, Bulman ZP, Landersdorfer CB, Smith N, Lenhard JR, Bulitta JB, Nation RL, Li J, Tsuji BT.

Infect Dis Ther. 2015 Dec;4(4):391-415. doi: 10.1007/s40121-015-0093-7. Epub 2015 Dec 8.

25.

A candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus.

Li QS, Lenhard JM, Zhan Y, Konvicka K, Athanasiou MC, Strauss RS, Francke S.

Pharmacogenet Genomics. 2016 Feb;26(2):53-65. doi: 10.1097/FPC.0000000000000185.

PMID:
26524290
26.

Disciplines, models, and computers: the path to computational quantum chemistry.

Lenhard J.

Stud Hist Philos Sci. 2014 Dec;48:89-96.

PMID:
25571750
27.

Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype.

Lenhard JR, von Eiff C, Hong IS, Holden PN, Bear MD, Suen A, Bulman ZP, Tsuji BT.

Antimicrob Agents Chemother. 2015 Feb;59(2):1347-51. doi: 10.1128/AAC.04508-14. Epub 2014 Dec 1.

28.

Thioredoxin-mimetic peptide CB3 lowers MAPKinase activity in the Zucker rat brain.

Cohen-Kutner M, Khomsky L, Trus M, Ben-Yehuda H, Lenhard JM, Liang Y, Martin T, Atlas D.

Redox Biol. 2014 Jan 9;2:447-56. doi: 10.1016/j.redox.2013.12.018. eCollection 2014.

29.

4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.

Yang SM, Tang Y, Rano T, Lu H, Kuo GH, Gaul MD, Li Y, Ho G, Lang W, Conway JG, Liang Y, Lenhard JM, Demarest KT, Murray WV.

Bioorg Med Chem Lett. 2014 Mar 1;24(5):1437-41. doi: 10.1016/j.bmcl.2013.12.075. Epub 2013 Dec 27.

PMID:
24405703
30.

4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.

Yang SM, Tang Y, Zhang R, Lu H, Kuo GH, Gaul MD, Li Y, Ho G, Conway JG, Liang Y, Lenhard JM, Demarest KT, Murray WV.

Bioorg Med Chem Lett. 2013 Dec 15;23(24):6773-6. doi: 10.1016/j.bmcl.2013.09.096. Epub 2013 Oct 9.

PMID:
24153205
31.

Lipogenic enzymes as therapeutic targets for obesity and diabetes.

Lenhard JM.

Curr Pharm Des. 2011;17(4):325-31. Review.

PMID:
21375498
32.

Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.

Patch RJ, Searle LL, Kim AJ, De D, Zhu X, Askari HB, O'Neill JC, Abad MC, Rentzeperis D, Liu J, Kemmerer M, Lin L, Kasturi J, Geisler JG, Lenhard JM, Player MR, Gaul MD.

J Med Chem. 2011 Feb 10;54(3):788-808. doi: 10.1021/jm101063h. Epub 2011 Jan 10.

PMID:
21218783
33.

Photophysical properties of the series fac- and mer-(1-phenylisoquinolinato-N∧C2')(x)(2-phenylpyridinato-N∧C2')(3-x)iridium(III) (x = 1-3).

Deaton JC, Young RH, Lenhard JR, Rajeswaran M, Huo S.

Inorg Chem. 2010 Oct 18;49(20):9151-61. doi: 10.1021/ic1002594.

PMID:
20839842
34.

Diabetogenic effect of a series of tricyclic delta opioid agonists structurally related to cyproheptadine.

Codd EE, Baker J, Brandt MR, Bryant S, Cai C, Carson JR, Chevalier KM, Colburn RW, Coogan TP, Dax SL, Decorte B, Kemmerer M, Legrand EK, Lenhard JM, Leone AM, Lin L, Mabus JR, McDonnell ME, McMillian MK, McNally JJ, Stone DJ Jr, Wang CY, Zhang SP, Flores CM.

Toxicol Sci. 2010 Oct;117(2):493-504. doi: 10.1093/toxsci/kfq200. Epub 2010 Jul 8.

PMID:
20616206
35.

MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.

Gregoire FM, Zhang F, Clarke HJ, Gustafson TA, Sears DD, Favelyukis S, Lenhard J, Rentzeperis D, Clemens LE, Mu Y, Lavan BE.

Mol Endocrinol. 2009 Jul;23(7):975-88. doi: 10.1210/me.2008-0473. Epub 2009 Apr 23.

36.

Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.

Song F, Lu S, Gunnet J, Xu JZ, Wines P, Proost J, Liang Y, Baumann C, Lenhard J, Murray WV, Demarest KT, Kuo GH.

J Med Chem. 2007 Jun 14;50(12):2807-17. Epub 2007 May 15.

PMID:
17500511
37.

An EPR study of two-electron sensitization by fragmentable electron donors.

Eachus RS, Muenter AA, Pawlik TD, Lenhard JR.

J Phys Chem B. 2005 May 26;109(20):10126-36.

PMID:
16852227
38.

2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV.

Haffner CD, McDougald DL, Reister SM, Thompson BD, Conlee C, Fang J, Bass J, Lenhard JM, Croom D, Secosky-Chang MB, Tomaszek T, McConn D, Wells-Knecht K, Johnson PR.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5257-61. Epub 2005 Sep 15.

PMID:
16168640
39.

IBC's 6th International Symposium on Obesity and 3rd International Symposium on Insulin Resistance: March 22-25, 1999, Washington, DC.

Lenhard JM, Cobb JE.

Expert Opin Investig Drugs. 1999 Jun;8(6):911-6. No abstract available.

PMID:
15992140
40.

Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.

Lenhard JM, Croom DK, Minnick DT.

Biochem Biophys Res Commun. 2004 Nov 5;324(1):92-7.

PMID:
15464987
41.

Structure-based design of potent retinoid X receptor alpha agonists.

Haffner CD, Lenhard JM, Miller AB, McDougald DL, Dwornik K, Ittoop OR, Gampe RT Jr, Xu HE, Blanchard S, Montana VG, Consler TG, Bledsoe RK, Ayscue A, Croom D.

J Med Chem. 2004 Apr 8;47(8):2010-29.

PMID:
15056000
42.

Preclinical developments in type 2 diabetes.

Lenhard JM, Gottschalk WK.

Adv Drug Deliv Rev. 2002 Nov 5;54(9):1199-212. Review.

PMID:
12393301
43.

Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662.

Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG.

Biochemistry. 2002 May 28;41(21):6640-50.

PMID:
12022867
44.

Select HIV protease inhibitors alter bone and fat metabolism ex vivo.

Jain RG, Lenhard JM.

J Biol Chem. 2002 May 31;277(22):19247-50. Epub 2002 Apr 5.

45.

PPAR gamma/RXR as a molecular target for diabetes.

Lenhard JM.

Receptors Channels. 2001;7(4):249-58. Review.

PMID:
11697231
46.

Metabolic complications associated with antiretroviral therapy.

Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM.

Antiviral Res. 2001 Sep;51(3):151-77. Review.

PMID:
11448728
47.

β-Adrenoceptor assays.

Kenakin T, Lenhard JM, Paulik MA.

Curr Protoc Pharmacol. 2001 May;Chapter 4:Unit4.6. doi: 10.1002/0471141755.ph0406s00. No abstract available.

PMID:
21971805
48.

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

Lenhard JM, Croom DK, Weiel JE, Winegar DA.

Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2625-9.

PMID:
11116063
49.

Bone mineral loss in HIV-positive patients receiving antiretroviral therapy.

Weiel JE, Lenhard JM.

AIDS. 2000 Sep 29;14(14):2218-9. No abstract available.

PMID:
11061673
50.

HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.

Lenhard JM, Furfine ES, Jain RG, Ittoop O, Orband-Miller LA, Blanchard SG, Paulik MA, Weiel JE.

Antiviral Res. 2000 Aug;47(2):121-9.

PMID:
10996400

Supplemental Content

Loading ...
Support Center